1561. Toujeo-H-C-309-PSUSA-1751-201904 1562. Brineura-H-C-PSUSA-00010596-201904 1563. Neofordex-H-C-PSUSA-00010480-201909 1564. Exjade-H-C-PSUSA-00000939-201910 1565. Pregabalin Pfizer-H-C-PSUSA-00002511-202001: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation 1566. Onpattro-H-C-PSUSA-00010715-202002 1567. Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation 1568. Bortezomib Fresenius Kabi-H-C-PSUSA-00000424-202004 1569. Fycompa-H-C-PSUSA-00009255-202007: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation 1570. Angiotensin-II-receptor antagonists (sartans) : Scientific conclusions - Impact of the Article 5(3) scientific opinion on nitrosamines 1571. Votrient-H-C-PSUSA-00002321-201910 1572. Ninlaro-H-C-PSUSA-00010535-201911 1573. EndolucinBeta-PSUSA-00010391-201912 1574. Tivicay-H-C-PSUSA-00010075-202001 1575. Saxenda-H-C-PSUSA-00001892-201912 1576. Byetta-PSUSA-00009147-202003 1577. Nimenrix-H-C-PSUSA-00010044-202004 1578. Inbrija-H-C-PSUSA-00107800-202006 1579. Lysodren-H-C-521-PSUSA-00002075-202004 1580. Trulicity-H-C-PSUSA-10311-202009 1581. Adakveo-H-C-PSUSA-00010888-202011 1582. Stelara-H-C-PSUSA-00003085-202012 : Scientific conclusions and grounds for the variation to the terms of the marketing authorisation 1583. Tecfidera-H-C-PSUSA-00010143-202103 1584. Rydapt-H-C-PSUSA-00010638-202010 1585. Revlimid-H-C-PSUSA-00001838-202012 1586. Lumigan-H-C-PSUSA-00000413-202103 1587. Ultomiris-H-C-PSUSA-00010787-202106 1588. Mysimba-H-C-PSUSA-00010366-202109: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation 1589. Lutathera-H-C-PSUSA-00010643-2202112 1590. Yescarta-H-C-PSUSA-00010703-202110